Maipl Therapeutics

18 Circle Road
Scarsdale, NY 10583

Phone: 646-531-1100


General Information:

Maipl Therapeutics develops small molecule new drugs to treat endometriosis-related pain, idiopathic pulmonary fibrosis (IPF), and other conditions.  The company’s platform is based on breakthrough FP antagonist (FPA) lead compounds licensed from Ferring Pharmaceuticals.  The FPA leads are potent and highly selective inhibitors of prostaglandin F2α signaling, with therapeutics potentials for menstrual pain, fibrosis, and inflammatory conditions in which elevated F2α causes a detrimental effect.  FPAs have virtually no impact on other essential prostaglandin functions, unlike NSAIDs and COX-2 that are associated with rare but serious GI, renal, and CV side effects.  Maipl has the first-mover advantage in their focused therapeutic areas, and will continue to explore new indications.